6532 related articles for article (PubMed ID: 2403853)
1. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
2. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
Jacquillat C; Khayat D; Banzet P; Weil M; Fumoleau P; Avril MF; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer; 1990 Nov; 66(9):1873-8. PubMed ID: 2224783
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
Khayat D; Cour V; Bizzari JP; Aigner K; Borel C; Cohen-Alloro G; Weil M; Auclerc G; Buthiau D; Bousquet JC
Am J Clin Oncol; 1991 Oct; 14(5):400-4. PubMed ID: 1951178
[TBL] [Abstract][Full Text] [Related]
5. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Nguyen BB; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun JR; Clavel M
Cancer Radiother; 2003 Feb; 7(1):1-8. PubMed ID: 12648711
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
7. Neurological toxicity during metastatic melanoma treatment with fotemustine.
Khalil Z; Pageot N; Carlander B; Guillot B
Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of fotemustine in patients with metastatic malignant melanoma.
Falkson CI; Falkson G; Falkson HC
Invest New Drugs; 1994; 12(3):251-4. PubMed ID: 7896545
[TBL] [Abstract][Full Text] [Related]
9. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
10. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Ulrich J; Gademann G; Gollnick H
J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
[TBL] [Abstract][Full Text] [Related]
11. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Bui BN; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre ME; De Gislain C; Bensadoun RJ; Clavel M
Melanoma Res; 2003 Feb; 13(1):97-103. PubMed ID: 12569292
[TBL] [Abstract][Full Text] [Related]
13. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S
Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900
[No Abstract] [Full Text] [Related]
14. Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
Khayat D; Bizzari JP; Frenay M; Naman H; Weil M; Goupil A; Namer M; Rouesse J; Banzet P; Jacquillat C
J Natl Cancer Inst; 1988 Nov; 80(17):1407-8. PubMed ID: 3172267
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Avril MF; Bonneterre J; Delaunay M; Grosshans E; Fumoleua P; Israel L; Bugat R; Namer M; Cupissol D; Kerbrat P
Cancer Chemother Pharmacol; 1990; 27(2):81-4. PubMed ID: 2249337
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Mohr P; Makki A; Breitbart E; Schadendorf D
Melanoma Res; 1998 Apr; 8(2):166-9. PubMed ID: 9610871
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.
Le Cesne A; Chabot G; Bérille J; Lucas C; Baud M; Gouyette A; Marty M; Le Chevalier T
Lung Cancer; 1995 Aug; 13(1):69-78. PubMed ID: 8528641
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
20. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Calabresi F; Aapro M; Becquart D; Dirix L; Wils J; Ardizzoni A; Gerard B
Ann Oncol; 1991 May; 2(5):377-8. PubMed ID: 1954183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
